SecBot SecBot
SECBOTREPLAY Home › Report › RYTM

RYTM · On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive…

RHYTHM PHARMACEUTICALS, INC. · 8-K filed Jun 15, 2026 at 16:07 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jun 15, 2026 at 16:07 ET

On June 13 and June 15, 2026, Rhythm Pharmaceuticals released positive interim clinical data from its Phase 2 trial of setmelanotide in Prader-Willi syndrome (PWS) and multiple data presentations across acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and PWS at ENDO 2026. Six-month PWS data showed a -3.06% mean BMI reduction, preservation of lean mass, and clinically meaningful hyperphagia improvements, with 8 of 10 moderate-to-severe patients achieving a ≥7-point HQ-CT reduction. Additional data showed -18.9% mean BMI reduction at 2.5 years in HO with setmelanotide, encouraging 1-year oral bivamelagon data in HO, and real-world BBS outcomes. The company confirmed plans to advance into Phase 3 trials for PWS, reinforcing the MC4R agonism thesis and expanding the addressable market opportunity.

  • Setmelanotide in PWS: -3.06% mean BMI reduction at Month 6 (N=17); 8/10 moderate-to-severe hyperphagia patients achieved ≥7-point HQ-CT improvement
  • Setmelanotide in acquired HO: -18.9% mean BMI reduction sustained at 2.5 years (n=11)
  • Oral bivamelagon in HO: mean BMI reductions of 6.7% to 16.6% across dosing cohorts at Week 52 (n=26)
  • Real-world BBS data (n=286): 62% of adults achieved ≥10% body weight loss at 12 months; significant reduction in outpatient obesity-related visits

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access